The abstract is read at the publisher; the summary is JClub's.
Perioperative pembrolizumab added to neoadjuvant platinum-doublet chemotherapy nearly doubled 5-year event-free survival in resectable stage II–IIIB (N2) NSCLC, reaching 49.9% vs 26.5%.
- Why it matters: Early-stage resectable NSCLC needs durable benefit beyond standard neoadjuvant chemotherapy and surgery, with uncertainty about long-term outcomes and quality-of-life effects.
- What they did: In the phase III randomized KEYNOTE-671 trial, participants received 4 cycles of pembrolizumab 200 mg or placebo every 3 weeks with chemotherapy, then surgery, followed by adjuvant pembrolizumab or placebo for up to 13 cycles; outcomes were assessed at 5 years.
- The result: After a median 60.4 months follow-up, 5-year overall survival was 64.6% vs 53.6% (HR 0.74), with no detriment to health-related quality of life and safety consistent with known profiles.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.